Cofactor Genomics
-62%
est. 2Y upside i
Cofactor closes the precision medicine gap with predictive diagnostics
Rank
#1609
Sector
Biotechnology, Diagnostics
Est. Liquidity
~4Y
Data Quality
Data: MediumCofactor Genomics presents a risky equity opportunity with moderate upside potential, primarily driven by its innovative RNA-based diagnostic platform and recent Medicare approval for OncoPrism®.
Last updated: March 10, 2026
Cofactor Genomics successfully scales commercialization of OncoPrism® across U.S. cancer care networks, leveraging Medicare approval and strategic partnerships. This drives revenue to $30M+ by 2028, leading to an acquisition by a major diagnostic player (e.g., Labcorp) at a $150M+ valuation, providing significant returns for common shareholders.
The company achieves moderate market penetration with OncoPrism®, growing revenue to $10-12M by 2028. Continued high capital intensity necessitates another funding round at a modest step-up, or a smaller acquisition at a $75M valuation, resulting in a moderate return for common stock after preferences.
Commercialization efforts face significant headwinds due to intense incumbent competition, slower-than-expected adoption, or regulatory challenges. Revenue growth stalls, leading to a down round or an exit below the current valuation, where the $26M in liquidation preferences wipe out most, if not all, common stock value.
Preference Stack Risk
severeWith $26M in total funding and an estimated $50M valuation, investors hold $26M in liquidation preferences, meaning common stock would receive nothing in an exit below $26M and significantly less in an exit between $26M and $50M.
Dilution Risk
highAs a Series A company with very high capital intensity, Cofactor Genomics will likely require multiple additional funding rounds, leading to further dilution for existing equity holders.
Secondary Liquidity
noneThere is currently no active secondary market or tender offers for Cofactor Genomics' equity, limiting liquidity options for employees.
Questions to Ask at the Interview
Strategic questions based on Cofactor Genomics's data — designed to show you've done your homework.
- 1
“How is Cofactor Genomics planning to leverage the strategic investment from Labcorp to mitigate the incumbent threat from larger players like Caris Life Sciences and Foundation Medicine, and what is the long-term vision for this partnership?”
- 2
“With Medicare approval for OncoPrism® and a new CEO focused on commercial growth, what are the specific milestones and timelines for scaling commercial operations, expanding into new cancer indications, and achieving profitability within the next 2-3 years?”
- 3
“Given the high capital intensity of the diagnostics sector and the current preference stack, what is the company's strategy for future funding rounds, and what is a realistic timeline and expected mechanism for providing liquidity to employees holding equity?”
Community
Valuation Sentiment
Our model estimates -62% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.